Product Description: MNS (NSC 170724), the beta-nitrostyrene derivative, is a potent tyrosine kinase inhibitor and a broad-spectrum antiplatelet agent. MNS completely inhibits U46619, ADP-, arachidonic acid-, collagen-, and thrombin-induced platelet aggregation with IC50 values of 2.1, 4.1, 5.8, 7.0, and 12.7 μM, respectively. MNS inhibits Src, Syk, and FAK with IC50 of 27.3, 2.8, and 97.6 μM, respectively[1][2].
Applications: Cancer-Kinase/protease
Formula: C9H7NO4
References: [1]Wang WY, et al. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007;74(4):601-611./[2]Wang WY, et al. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006;70(4):1380-1389.
CAS Number: 1485-00-3
Molecular Weight: 193.16
Compound Purity: 99.60
Research Area: Cancer
Solubility: DMSO : 50 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: Src;Syk
English
Deutsch
